AVR anteris technologies global corp.

More on cormatrix, page-5

  1. 1,125 Posts.
    lightbulb Created with Sketch. 59
    While the numbers are eye opening..... chronic inflamation in 11 of 12 cases, calcification (3/12) product degeneration (9/12) necrosis !!!!! (5/12) and calcification (3/12).. the report identified that 12 of 532 patients had product explanted.....just 2.3% of cases. Product seemed to work for the vast majority.... but the 2.3 % is one patient in 43. Two issues. Who wants to risk being pt no 43??????? And....is it not the product being unsuitable or...the individual patient. Could be that certain patients are sensitive to cormatrix and CC is the product for patients at high risk of reaction. Sub category of patients CC can target perhaps without treading on toes.

    However there are risks with in medicine and surgery but 1in 43 seems a tad high.

    Just my two cents worth.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.91
Change
0.290(5.16%)
Mkt cap ! $91.59M
Open High Low Value Volume
$5.79 $6.19 $5.79 $17.15K 2.906K

Buyers (Bids)

No. Vol. Price($)
1 38 $5.90
 

Sellers (Offers)

Price($) Vol. No.
$6.10 170 1
View Market Depth
Last trade - 16.10pm 04/07/2025 (20 minute delay) ?
AVR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.